Leerink Swann initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with an Outperform rating and a price target of $46.00.

For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.

Shares of Sage Therapeutics closed at $33.40 yesterday.